AzTrials
AzTrials

AtherosclerosisNCT00534014

Vitamin C and Cardiovascular Risk

A study testing Vitamin C in people with Atherosclerosis and Type 2 Diabetes, run by University of New Mexico at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Study Goal #1: Determine the optimal oral dose of vitamin C to reduce surrogate markers of atherosclerosis (blockages in blood vessels) following the consumption of an atherogenic high fat lunch in type 2 diabetic individuals. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Atherosclerosis, Type 2 Diabetes
What is being tested?
Vitamin C
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
8 participants
Where
1 siteUnited States
Study dates
Jan 2006to May 2007
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Type 2 diabetic for at lease 6 months
  • Body mass index less than 40kg/m2
  • Normal EEG's
  • Normal test results from screening visit.

Who cannot join

  • Known vascular disease
  • Uncontrolled hypertension (>140/90 mmHg) or marked hyperlipidemia (serum low denisity lipoprotein >4.1 mmol/L or serum triglycerides > 7.8 mmol/L)
  • Pregnancy
  • Cigarette smoking
  • Currently taking coumadin
  • Recent use of antioxidant supplements or asprin.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of New Mexico , Clinical Translational Science Center

    Albuquerque, New Mexico, 87131

Other trials in United States

About this study

Official title: Vitamin C Therapy in Type 2 Diabetes and Cardiovascular Risk

Study Goal #1: Determine the optimal oral dose of vitamin C to reduce surrogate markers of atherosclerosis (blockages in blood vessels) following the consumption of an atherogenic high fat lunch in type 2 diabetic individuals.

Study Goal #2: After conducting the original study, we found that vitamin E was not effective in reducing the markers of oxidative stress, hypercoagulation, inflammation, and metabolic parameters in patients with type 2 diabetes.

To date, data from randomized trials have largely demonstrated no significant benefit of vitamin E supplementation on the prevention of primary and/or secondary cardiovascular disease as once thought. Therefore, we decided to amend our current protocol to add a Part B to study only the effects of vitamin C at the following doses: 500 mg, 1000 mg, and 2000 mg daily (and include a placebo arm, as well.

Read the detailed description

More than 70% of type 2 diabetic individuals will die of atherosclerotic disease (1). This is partially explained by the abnormal lipid profile frequently observed in type 2 diabetes. These patients are also frequently afflicted with "Syndrome X," an assortment of risk factors for atherosclerosis, including hypertension, abdominal obesity, hyperuricemia, prothrombotic and proinflammatory states, and increased plasminogen activator inhibitor type I (PAI-1) (2).

Several approaches have been suggested to reduce the risk of atherosclerosis in type 2 diabetic individuals. Changes in lifestyle leading to increased exercise and weight loss will result in the reduction of adipose stores (and restore tissue sensitivity to insulin). However, this approach is very difficult for many individuals to achieve. For them, this can be supplemented with medications such as aspirin, angiotensin inhibitors, angiotensin receptor blockers, and the statins. Unfortunately, each of these medications is either expensive and/or includes undesirable side effects (3). In addition, clinical experience shows that many patients are against taking medication for cultural reasons and/or fear of long-term unknown consequences.

For these reasons, there is great interest in using vitamins to reduce atherogenic risk. More than half of the U.S. adult population consumes vitamins on a regular basis. They are inexpensive and easily accessible in grocery stores and health food stores. The FDA does not consider them as "drugs" and they undergo a less rigorous approval procedure (4,5). Vitamins are natural compounds found in the body, and many individuals do not consider them drugs, but feel they are simply fortifying their bodies against disease.

There is currently a focus on vitamins that are antioxidants, including vitamin C. Patients with diabetes usually have a decreased antioxidant status, which leads to increased oxidative stress and vascular dysfunction (6,7). Oxidative stress refers to the excessive production of oxygen free radical species, which damage their surrounding molecules, and this leads to the increased release of inflammatory mediators, oxidation of low-density lipoproteins (LDL), and increased coagulation (7).

Vitamin C, another antioxidant, has been shown to regenerate Vitamin E, and in patients with increased oxidative stress (i.e. patients with conditions such as diabetes mellitus, coronary artery disease, and hypercholesterolemia), it restores endothelium-dependent artery vasodilation, and may reverse endothelial dysfunction in peripheral arteries (6). It has been hypothesized that supplementation of vitamin C may be more effective than vitamins taken together.

The hypothesis that atherosclerosis may be prevented by blocking the oxidative metabolism of LDL cholesterol, hence decreasing its uptake into the arterial lumen, is what incited the interest in vitamin C for treating coronary heart disease (CHD). Basic science and animal studies had shown beneficial effects of vitamin C on several different stages of the atherosclerotic process. This was followed by several observational studies on patients with no initial coronary artery disease, which suggested that vitamin C lowered the risk of future CHD. However, this was followed by several large randomized control trials, the majority of which showed no benefit of vitamin C in the prevention of CHD in patients with at least one coronary risk factor. However, this did not answer the question of whether vitamin C was beneficial in differeing doses.

In 2002, Fang et al. published a study that investigated the efficacy of vitamins C and E on the prevention of transplant-associated arteriosclerosis (another highly oxidative state). The primary outcome was change in average intimal index (plaque area divided by vessel area), which was measured with intavascular ultrasonography (IVUS). The vitamin C and E plasma concentrations were measured at baseline and at 1-year follow-up. At follow-up the placebo group showed a significant increase but the treatment group showed no change. The authors concluded that early progression of transplant-associated coronary arteriosclerosis is delayed with combined vitamin C and E therapy (6,10). In 2003, Salonen et al. published the six-year effects of combined vitamin C and E from the ASAP (Antioxidant Supplementation in Atherosclerosis Prevention) study, which studied the effects of supplemented doses on the progression of common carotid atherosclerosis in middle-aged high-risk men and women, using high-resolution ultrasound to assess this outcome. The group receiving combined vitamins showed a decrease in rate of progression of carotid intimal thickness, but this effect was limited to men only (8,10). In the Heart Protection Study (2002), a combination of synthetic vitamin E, vitamin C, and beta-carotene daily had no effect on the incidence of cardiovascular events in a group of approximately 20,000 high-risk individuals (10).

Therefore, not all studies showed positive benefits. Vitamin C has been shown to reduce overall oxidative stress by scavenging free readicals within the body (11). Some trials failed to report antioxidant levels, making compliance difficult to measure (8) (except through pill counting - and unfortunately, volunteers can dispose medications prior to visit, in order to give the image of compliance). Some trials used suboptimal timing regarding administration of antioxidant vitamins in relation to meals (1). Also, it is not known just what exactly is the optimal dosage of vitamins C is. The doses of vitamin C has differed in these trials (8); some investigators hypothesize that at least 500 mg/day of vitamin C are effective for slowing the progression of atherosclerosis, but speculation is rampant (7,8).

Based on the data from these studies (1,7,8), we believe that only sufficient doses of vitamins C will be effective for slowing the progression of atherosclerosis. It is our goal to find the optimal dosing combination. We will use a high-risk population (diabetic volunteers) because they are known to have high oxidative stress and may benefit tremendously from this therapy.

Being tested
Vitamin C
Medical subject headings
Atherosclerosis, Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Vitamin CDietary supplement

    Arm A = 0 mg Vitamin C, Arm B = 250 mg Vitamin C, Arm C = 500 mg Vitamin C, Arm D = 1000 mg Vitamin C

Study groups in NCT00534014
Study groupRoleWhat they receive
APlacebo comparator0 mg of Vitamin C
Receives: Dietary Supplement: Vitamin C
BActive comparator250 mg Vitamin C
Receives: Dietary Supplement: Vitamin C
CActive comparator500 mg Vitamin C
Receives: Dietary Supplement: Vitamin C
DActive comparator1000 mg Vitamin C
Receives: Dietary Supplement: Vitamin C

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To determine the optimal oral dose of vitamin C and E to reduce surrogate markers of atherosclerosis (blockages in blood vessels) following the consumption of an atherogenic high fat lunch in type 2 diabetic individuals.

    Measured: 8 weeks

Secondary outcomes (1)
  1. To study the effects of vitamin C on fibrinogen, insulin, glucose, PAI-1, adiponectin, free MDA, Oxy LDL,CRP, cholesterol, and FFA.

    Measured: 8 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Sep 2007 (estimated)
  2. Study startJan 2006
  3. Primary completionMar 2007
  4. Study completionMay 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
8 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00534014
Sponsor's protocol ID
04-319B
Status last verified
Mar 2024
First submitted
20 Sep 2007
Last updated
12 Mar 2024
Results posted
No
Data monitoring committee
Yes

Publications

  • Gutierrez AD, Duran-Valdez E, Robinson I, de Serna DG, Schade DS. Does short-term vitamin C reduce cardiovascular risk in type 2 diabetes? Endocr Pract. 2013 Sep-Oct;19(5):785-91. doi: 10.4158/EP12431.OR.

    PubMed 23757614

Questions about this trial

What is this clinical trial studying?

A study testing Vitamin C in people with Atherosclerosis and Type 2 Diabetes, run by University of New Mexico at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To determine the optimal oral dose of vitamin C and E to reduce surrogate markers of atherosclerosis (blockages in blood vessels) following the consumption of an atherogenic high fat lunch in type 2 diabetic individuals. (time frame: 8 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00534014, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in